# HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC

> **NCT05582278** · PHASE2 · UNKNOWN · sponsor: **Wen Li** · enrollment: 60 (estimated)

## Conditions studied

- Unresectable Hepatocellular Carcinoma

## Interventions

- **DRUG:** D-TACE
- **DRUG:** HAIC
- **DRUG:** Lenvatinib
- **DRUG:** tislelizumab

## Key facts

- **NCT ID:** NCT05582278
- **Lead sponsor:** Wen Li
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-01
- **Primary completion:** 2024-01-01
- **Final completion:** 2024-01-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05582278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05582278, "HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05582278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*